Neotigason (acitretin)
The information on this web page is intended for patients (or their caregivers) prescribed Neotigason (acitretin) following consultation with a healthcare professional in Ireland.
If you experience any side effects (adverse events), talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet.
You can report side effects directly via the national reporting system: HPRA Pharmacovigilance, Earlsfort Terrace, Dublin, Ireland. Tel: 01 6764971; Fax: 01 6762517; Email: medsafety@hpra.ie ; Website: www.hpra.ie
Side effects should also be reported directly to Teva using the Reporting Side Effects Form, or telephone +44 (0)207 540 7117, or email uk.safety@tevauk.com.
Pregnancy Prevention Programme
Neotigason capsules contain the active ingredient acitretin, which is belongs to a group of medicines known as ‘retinoids’.
This medicine can seriously harm an unborn baby (the medicine is said to be ‘teratogenic’). You must not take Neotigason if you are pregnant. If there is any chance you could become pregnant, you must follow the precautions of the ”Pregnancy prevention programme” outlined in the package leaflet and the patient reminder card.
Teva provides pregnancy prevention programme (PPP) materials for patients treated with Neotigason (acitretin) 10 mg and 25 mg hard capsules:
Further information (such as how to take Neotigason, special warnings and possible side effects) is included in the package leaflet, which is supplied in each pack of Neotigason. Please read the leaflet carefully.
An electronic copy of the package leaflet can be accessed from the Health Products Regulatory Authority (HPRA) website here.
If you have any queries please contact your doctor or pharmacist or Teva's Medical Information team on +44 207 540 7117 or email medinfo@tevauk.com
Get in touch with Teva
We're here to assist patients and healthcare professionals with information about our medicines, devices and services.Teva Medical Information
Our Medical Information Service can help with enquiries about Teva's medicines, devices and services.
Tel: +44 207 540 7117
Email: medinfo@tevauk.com
They can also provide copies of regulatory documents such as Patient Information Leaflets, or Summary of Product Characteristics.
Reporting Suspected Side Effects
You can report side effects directly via the national reporting system: HPRA Pharmacovigilance, Earlsfort Terrace, Dublin, Ireland. Tel: 01 6764971; Fax: 01 6762517; Email: medsafety@hpra.ie ; Website: www.hpra.ie
Side effects should also be reported directly to Teva:
Tel: +44 207 540 7117
Email: uk.safety@tevauk.com
Online: Side Effect Reporting Form